All Industries

Wormhole Foundation Awards Contributor Grant to Zpoken to Advance Trustless ZK Transfers for NEAR and Ethereum

Wormhole Foundation

The Wormhole Foundation, a research and development organization dedicated to interoperability between blockchains, is excited to announce a Contributor Grant to the team at Zpoken. The addition of the Zpoken team to Wormhole’s decentralized set of contributors is a major step forward for Wormhole's platform in the context of trustless verification of cross-chain messages using Zero Knowledge (ZK) technology. Zpoken has established itself as a key player in the field of ZK technology globally, notably with its work on the NEAR ZK Light Client. Wormhole’s capabilities will include the first trustless, zero knowledge Ethereum-to-NEAR corridor. This bi-directional bridge will enable all major NEAR and Ethereum-based assets to be transferred across chains without needing to trust any centralized actors for message verification, despite Wormhole currently having the most trusted set of decentralized validators ( see Uniswap’s Bridge Assessment ), the Wormhole Guardians. Given Wormhole’s modular and flexible technology stack, Wormhole Guardians will continue to verify messages for any corridor not yet integrated with ZK proofs. Robinson Burkey, Co-founder and Chief Commercial Officer at Wormhole Foundation, remarked, "Offering our developer community trustless verification for their messages between Ethereum and NEAR will be a major milestone. The Foundation is very excited to add Zpoken to the decentralized team of collaborators and the integration of their ZK technology into Wormhole's interoperability platform, and we look forward to rolling this technology out to developers." Mike Yezhov, CEO at Zpoken added, “Integrating cryptographic commitments into economic models to enhance the interoperability of the decentralized web is an incredibly exciting endeavor. We are thrilled to contribute our expertise in NEAR Zero-Knowledge light clients to some of the largest and most promising interoperability protocols within the Web3 ecosystem. This contribution represents a significant step forward in securing and streamlining the interaction between diverse blockchain networks, thereby unlocking new possibilities for decentralized applications and services.” For further inquiries and collaboration opportunities, please contact the Wormhole Foundation at hello@wormhole.foundation. About Zpoken Zpoken is a full-stack Web3 development organization that specializes in the development and implementation of ZK technology, cryptography solutions and decentralized tech. Their work on the Near ZK Light Client is instrumental in advancing the field of trustless cross-chain communication, offering a new paradigm of privacy and security in blockchain technology. About Wormhole Foundation The Wormhole Foundation is the steward of Wormhole - the world’s first generalized messaging protocol. Our mission is to empower passionate people in the research and development of blockchain interoperability technologies. Through grants, research, and ecosystem programs, we seek to enable teams to build secure, open-source, and decentralized products within the Wormhole ecosystem. If you’re interested in helping achieve our mission, follow us on Twitter or contact us at hello@wormhole.foundation. Contact Details Ditto PR Wahaj Khan +1 630-935-7684 wahaj@dittopr.co

February 06, 2024 09:02 AM Eastern Standard Time

Doceree Secures Patent for its Groundbreaking Technology Empowering Marketers to Elevate Patient-Physician Engagement Through Real-Time Triggers on EHR Platforms

Doceree

Doceree, the leading global healthcare marketing platform building unprecedented solutions for programmatic HCP marketing using proprietary data tools, today announced the grant of a patent by US Patent and Trademark Office (USPTO) for its distinguished feature ‘Triggers’ that uses clinical data as real-time prompts for messaging to HCPs on Electronic Health Record Platforms, in a HIPAA-compliant and privacy-forward way. In the United States, physicians possess the potential to enhance healthcare delivery by leveraging relevant information; however, the challenge lies in the timely accessibility of crucial data. Despite the ongoing digital transformation in the healthcare sector, Healthcare Professionals (HCPs) continue to face a notable gap in accessing up-to-date information, a resource that is currently exclusive to life sciences organizations. As the industry undergoes rapid digitization, the need for efficient information dissemination to empower healthcare providers becomes increasingly evident. Bridging this information gap, Doceree introduced Triggers- a technological solution designed to guarantee the delivery of optimal and well-informed care to patients. Doceree's groundbreaking patent, officially paves the way for the integration of Doceree Triggers into the pharmaceutical marketing landscape. This patent encompasses a sophisticated medical product processing system that employs a first graphical user interface connected to an Electronic Health Record (EHR) platform. The system is designed to display messages in real-time to medical providers, tailored to their patients' predefined conditions. These conditions are inputted into the patient's electronic health record during the interaction between the patient and the healthcare provider, encompassing crucial details such as definitions of international classifications of diseases (ICD) codes. This patent not only represents a pivotal achievement, affirming Doceree's pioneering strategy in revolutionizing the interaction between pharmaceutical marketing and healthcare professionals, but it also plays a crucial role in aiding Electronic Health Record (EHR) platforms. The patent ensures real-time clinical data mapping in a HIPAA-compliant manner, contributing to the optimization of EHRs for health data interoperability. This optimization holds significant importance in supporting clinical research efforts. The seamless integration of research and clinical care within a health system has the potential to boost clinical trial participation rates, enhance health outcomes, reduce the cost of care, and foster greater patient satisfaction. " This patent not only signifies our steadfast dedication to pushing the boundaries and creating pioneering solutions for addressing the industry's most intricate challenges but also stands as a significant milestone in our journey towards establishing leadership in healthcare innovation and technology," stated Harshit Jain MD, Founder, and Global CEO of Doceree. " Beyond its legal implications, this inaugural patent reflects the resilience and forward-thinking ethos that defines our company. It serves as the bedrock for sustained success in the ever-evolving landscape of innovation, embodying our commitment to continuous advancement. The issuance of this patent is a powerful reminder of what can be achieved through collaborative efforts and a shared dedication to our strategic objectives," he emphasized. Doceree Triggers stands out by offering pharmaceutical manufacturers a distinctive set of capabilities. It enables the strategic planning and coordination of healthcare provider and direct-to-consumer campaigns, leveraging comprehensive insights into patient and provider behaviors, including the evaluation of past and present script performance. The platform empowers users to activate media seamlessly across various channels, encompassing display, video, and connected TV, all while optimizing bids to enhance overall business outcomes. Real-time performance measurement is a key feature, providing immediate insights into each campaign's effectiveness. Moreover, Doceree Triggers facilitates the dynamic optimization of ongoing campaigns by automatically adjusting parameters, enhancing audience quality, boosting script lift, and maximizing overall media efficiency. This multifaceted approach ensures that pharmaceutical marketing efforts are not only well-informed but also agile and responsive, driving impactful results in the competitive landscape. About Doceree: Doceree is a global platform building unprecedented solutions for healthcare professional (HCP) messaging with proprietary data and advanced tools. Utilizing an extensive global network of digital endemic and point-of-care platforms, Doceree facilitates seamless and meaningful communication between life sciences brands and HCPs, ensuring delivery of highly personalized messages to HCPs at scale. To learn more, https://doceree.com/us/doceree-triggers/. Contact Details Doceree Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Doceree Tanya Singh +91 70420 89805 tanya.singh@doceree.com Company Website https://doceree.com/us/doceree-triggers/

February 06, 2024 09:00 AM Eastern Standard Time

Sienna Resources Expands Its Portfolio To Include Two Uranium Projects In The Athabasca Basin Region As Global Prices Hit A 16-Year High

Benzinga

By Faith Ashmore, Benzinga 2024 is off to an interesting start as uranium prices jumped to a 16-year high, a trend that started in mid-2021. After almost a decade of dormancy following the Fukushima nuclear accident, uranium prices have sky-rocketed 250% since 2021, when COVID disruptions started impacting price increases. While resistance to nuclear power still exists, the need to cut commissions and decreased animosity towards nuclear power is partly responsible for the rising demand. However, the growing demand is coupled with a decrease in supply and a wariness to purchase uranium from Russia. Biden has faced scrutiny for continuing the policy of importing uranium from Russia, which accounts for approximately one-third of the uranium used in the U.S. Additionally, other historical producers and supply are being disrupted; Kazakhstan’s lead uranium producer Kazatomprom (OTCMKTS: NATKY) announced recently that it may have to cut production in 2024 due to difficulties with sulphuric acid availability. Uranium suppliers are clearly a hot commodity at the moment. Recognizing this, Sienna Resources Inc. (OTCMKTS: SNNAF), a company focused on exploring and developing mineral resources, has gotten into the uranium market. Sienna Resources has recently expanded its portfolio in the Athabasca Basin of Saskatchewan, adding the "Uranium Town Project" and the "Dragon Uranium Project" to its collection. The Athabasca Basin region is renowned for its rich uranium deposits, and Sienna's acquisitions provide a sizeable land area spanning over 21,000 acres. The Uranium Town Project covers an area of 10,357 acres adjoining ∫ (NYSE: DNN), while the Dragon Uranium Project spans an impressive 10,845 acres bordering Cameco Corporation (NYSE: CCJ) – the world's largest producer of uranium. The Fraser Institute has ranked Saskatchewan as the third-most attractive mining jurisdiction globally, adding to the potential of these newfound projects. Adding these projects bolsters Sienna Resources' presence in the valuable Athabasca Basin region and potentially sets the stage for exciting exploration opportunities, in addition to the company's existing lithium and graphite projects. Jason Gigliotti, President of Sienna shared, “Uranium prices have hit a 16-year high this week and management feels that diversifying into uranium while keeping our lithium focus makes sense. Establishing a large footprint in the most prolific uranium address on the globe bordering the biggest name in uranium, Cameco, provides Sienna and Sienna shareholders with exposure to the best-performing sector in mining in the past year. Management continues to try to add projects that are accretive to the growth of Sienna and we have enough cash on hand to forward these projects.” Uranium is having a moment on the demand side and as the U.S. looks to decrease reliance on Russian importers, companies like Sienna Resources could stand to become industry leaders. Not to mention, uranium’s connection to greener energy makes it a valuable asset in the race to decrease carbon emissions. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 06, 2024 08:45 AM Eastern Standard Time

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy

Benzinga

By Jeremy Golden, Benzinga A clinical-stage biotechnology company has published promising preclinical data in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR). The data produced by Elicio Therapeutics Inc. (NASDAQ: ELTX) demonstrates how Elicio’s proprietary Amphiphile (AMP) lymph node-targeting immunotherapy platform, carrying cognate peptide and adjuvant cargos, boosted T cell receptor-modified T cell (TCR-T cell) therapies while enhancing anti-tumor function and eradicating solid tumors. According to Peter DeMuth, Ph.D., Chief Scientific Officer at Elicio Therapeutics, optimization of TCR-T cell therapy could potentially have wide-ranging therapeutic benefits in many previously intractable solid tumors. During the study, AMP immunotherapy enhanced the infiltration and function of TCR-T cells in the tumor microenvironment and led to epitope spreading against diverse tumor targets. Additionally, long-term protection against tumor recurrence in AMP-treated mice was associated with antigen spreading to additional tumor-associated antigens not targeted by the treatment. “In this study, we’ve demonstrated that boosting TCR-T cell therapy directly in the lymph nodes with AMP immunotherapy resulted in durable anti-tumor T cell responses and tumor eradication,” DeMuth said. “The AMP treatment uniquely promoted potent mechanisms for immune activation in lymph nodes to invigorate both adoptive and endogenous anti-tumor T cell immunity. Simple application to a variety of cancer targets including mKRAS, HPV E7 and NY-ESO-1 could elevate existing TCR-T cell therapies to generate powerful new combinations for hard-to-treat solid tumors.” Elicio Therapeutics is developing a pipeline of novel immunotherapies for the treatment of cancer. Three vaccine candidates are currently in Elicio Therapeutics’ pipeline: ELI-002, ELI-007 and ELI-008. Elicio’s proprietary AMP platform delivers investigational immunotherapeutics directly to the lymph nodes, sometimes referred to as the “brain center” of the immune system. In previous Elicio studies, the results found that AMP immunotherapy promoted specific trafficking and retention of payloads into lymph nodes, yielding enhanced T cell numbers, persistence and functional quality. Preliminary phase 1 data from the ongoing study of Elicio’s lead asset, ELI-002, demonstrated significant T cell responses – including both CD4+ and CD8+ – when administered as an adjuvant monotherapy in patients with pancreatic and colorectal cancers. The strength of the T cell response induced by ELI-002, an mKRAS-specific AMP vaccine, was further correlated to significant improvements in tumor biomarker response, along with reduced risk of progression and death. This indicates an association between the ELI-002 mechanism of action and clinical outcome. “This study adds to our growing body of preclinical and clinical evidence demonstrating the importance of the lymph nodes and the robust efficacy that our AMP immunotherapy strategy can potentially achieve for patients with solid tumors, both as a monotherapy and in combination with other strategies,” said Robert Connelly, Chief Executive Officer at Elicio Therapeutics. “The AMP platform provides attractive potential for broad and rapid application to clinical and developmental TCR-T cell programs. We look forward to finding the right partner to advance this promising combination into the clinic for patients with solid tumors.” Featured photo by National Cancer Institute on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 06, 2024 08:35 AM Eastern Standard Time

Image

How Alternative Recycling Models Like The One Offered By Aqua Metals (NASDAQ: AQMS) Could Be Key To The Shift To EVs And Sustainable Transportation

Benzinga

By Faith Ashmore, Benzinga The U.S.’s battery economy is without doubt far behind the likes of China and other countries that have prioritized building clean energy industries. The global expansion of the electric vehicle (EV) market in particular is a major driving force behind the importance of developing a strong battery sector. As the demand for EVs continues to rise due to environmental concerns and the shift towards more sustainable transportation, there is a growing need for a reliable supply of lithium-ion batteries, which are the primary energy storage technology in EVs. To ensure a consistent battery supply of critical minerals for the growing EV market, the United States must invest in the development of a robust domestic supply chain to meet soaring demand as the U.S. battery manufacturing sector is expected to rise to almost 1 terawatt-hour by 2030, up from just 90 gigawatt-hours (GWh) in 2022. Investing in the domestic market can reduce dependence on foreign sources, stimulate economic growth and support the transition to electrification and a clean energy economy. However, many experts are keen to draw attention to recycled materials and the crucial role they will play in the development of the sector and building a circular supply chain. The global demand for lithium-ion batteries seems set to skyrocket, with projections indicating a sevenfold increase between 2022 and 2030. These batteries are essential in various applications, including EVs, energy storage systems and portable electronics, marking them as a critical component of our increasingly electrified world. However, a significant challenge arises in the recycling of these batteries. Currently, the recycling process predominantly relies on end-of-life (EOL) batteries. This approach presents a potential bottleneck in the supply chain, as there is a waiting period for these batteries to reach their EOL. For instance, considering the 1.2 million EVs sold in the U.S., most of these vehicles will likely still be operational in 2033, delaying the availability of their batteries for recycling. This scenario underscores the need for innovative recycling strategies that can efficiently handle the impending surge in lithium-ion battery usage while ensuring a sustainable approach to battery lifecycle management. This is why alternative recycling models can be so crucial to a thriving domestic economy. Aqua Metals Inc. (NASDAQ: AQMS) is a company pioneering a new form of lithium-ion battery recycling. At the core of Aqua Metals' innovation is the AquaRefining process, a sophisticated system that transforms lithium battery ‘ black mass ’ – the industry term for the composite of shredded battery metals and manufacturing scraps ready to be recycled – into high-purity, reclaimed materials ready to be delivered back into the supply chain. In the upcoming years, a significant portion of recyclable materials is expected to come from scrap materials generated during manufacturing operations rather than from EOL batteries or totaled EVs. Lithium battery ‘gigafactories’ and manufacturing operations can produce around 10-15% scrap materials. Projecting out to 2030, this could amount to 100-150 gigawatt-hours of battery scrap material each year in the U.S. alone, which is equivalent to enough material for approximately 2.5 million EV batteries. Scrap materials are readily available to recyclers like Aqua Metals and contain relatively high concentrations of valuable and critical materials like lithium, cobalt, nickel and manganese. Since these materials were never part of a complete battery, they won't have the usual content of plastics, binders and structural steel that typically make it to recycling supply streams. By 2030, approximately 750,000 tonnes of critical battery material will need to be recycled annually in the U.S. alone. Aqua Metals has already announced plans for a 10,000-tonne facility at the Sierra ARC. Additionally, the company has plans for a co-located facility with its partners at 6K Energy, adding another 8,000 tonnes per year, and has announced plans to license its proprietary technology to international partners to increase global AquaRefining capacity even further. Each tonne of end-of-life batteries and scrap material, which is collectively known as "black mass," contains approximately $20,000 worth of valuable materials. With 750,000 tonnes of scrap each year, the worth of these materials could reach up to $15 billion annually. Aqua Metals, with its processing capacity of 18,000 tonnes per year, could potentially process as much as $360 million worth of critical battery metals each year. Companies like Aqua Metals are at the forefront of battery technology, redefining the recycling landscape with innovative technologies that are delivering a clear path to a sustainable domestic battery economy. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 06, 2024 08:30 AM Eastern Standard Time

Sick of Cold Calling? Emotionally Intelligent AI Could Help You Break Into The $325.7 Billion Market Opportunity Of MarTech

Benzinga

By Faith Ashmore, Benzinga Interested in investing in HiveSkill’s campaign? Click here to get started. The proliferation of social media platforms, the rise of mobile devices and the advancements in technology have made digital marketing the new norm. While print advertising is still far from being phased out, ad spending is increasingly being devoted to digital marketing. However, not all digital marketing is created equal, and it can be easy to get lost in the crowd. That’s why companies like HiveSkill that harness the power of AI are so integral in the next generation of marketing. HiveSkill offers a unique marketing solution characterized by customization, hyper-targeting and a foundation of trust and data. Its approach involves delivering context-driven marketing campaigns tailored to pre-qualified leads sourced from its industry-leading consumer database. Powered by advanced artificial intelligence, HiveSkill conducts thorough audience profiling, categorizing contacts into relevant interest groups or "buckets." This enables them to create the optimal audience for effectively conveying a company's story and messages. HiveSkill is successfully deploying competencies in multiple large industries while differentiating itself from the big tech companies like Meta (NASDAQ: META), Google (NASDAQ: GOOG), and Amazon (NASDAQ: AMZN). The global digital marketing software industry was valued at $49.4 billion in 2019 and is forecasted to grow at a CAGR of 17.4% from 2020 to 2027. The global marketing technology (MarTech) market was valued at $325.7 billion in 2022 and is expected to grow at a CAGR of 19.8% from 2023 to 2030. Not to mention, in 2021, the market for artificial intelligence in marketing was estimated at $15.84 billion, and it is projected to increase to more than $107.5 billion by 2028. HiveSkill seems to be firmly positioning itself at the nexus of all these growing industry segments. HiveSkill differentiates itself from competitors by harnessing the power of emotionally intelligent AI. Through its construction of a comprehensive database, utilizing entrepreneurial networks and strategic partnerships with Crunchbase and Hubspot, HiveSkill instills greater confidence in companies' marketing strategies. In a marketing landscape dominated by big tech alternatives, where businesses can often feel like insignificant drops in an overwhelming ocean, HiveSkill aims to provide the opposite experience. When businesses choose to collaborate with HiveSkill, they not only gain access to an extensive existing database and tools, but HiveSkill will also use existing infrastructure and leads to help build a unique “Hive” of engaged prospects, fostering a mutually beneficial feedback loop of data. Consequently, HiveSkill's database has transformed into a robust engine comprising millions of carefully curated and profiled contacts. This empowers them to effectively engage and connect with their desired target audiences, including "look-alike" segments. HiveSkill takes the guesswork out of chasing leads, which is why the company boasts the tagline of “All you need to do is close the deal.” Firmly positioned in highly lucrative markets, the company could be the next step in the evolution of digital marketing. The company is currently hosting an investment offering with a minimum investment of only $0.25. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 06, 2024 08:20 AM Eastern Standard Time

Making Your Money Work For You: Generating 9-13% Potential Passive Income Through Real Estate Investing With DLP Capital

Benzinga

By Austin DeNoce, Benzinga Explore the potential of real estate for passive income with DLP Capital’s real estate funds. As more people explore alternative sources of income and ways to combat inflation, the concept of passive income has become more appealing than ever. It’s a strategy that allows you to earn money with minimal day-to-day involvement. Imagine generating income through ventures that don’t require your constant attention – that’s the essence of passive income. From rental earnings to investment returns, passive income encompasses a range of opportunities with the potential to provide financial security and freedom, allowing you to enjoy life more fully. Real Estate As An Avenue For Passive Income Real estate is a widely touted avenue for generating passive income. However, it’s not just about buying property; it’s about smart investing and reaping the benefits without the day-to-day hassles of active management. Whether it’s through rental income, property appreciation or investment funds, real estate offers a tangible asset that can yield substantial returns. With that in mind, exploring real estate-backed funds like those offered by DLP Capital is a great place to start. DLP Capital's funds are designed to cater to a variety of investor profiles, focusing on both financial returns and, in many cases, social impact through workforce housing initiatives. This holistic approach to investment, balancing profitability with societal contribution, is what sets DLP Capital apart in the crowded field of real estate investment firms. Explore DLP Capital’s website for its real estate funds, summarized below. The DLP Real Estate Funds DLP Lending Fund: The DLP Lending Fund provides capital to builders and operators to create and preserve affordable workforce housing while scaling the businesses of its sponsors. It focuses on secured, short-term first-person loans for non-owner-occupied single-family and multifamily mortgages and targets annual returns of 9-10%. DLP Building Communities Fund: The DLP Building Communities Fund invests in the development, acquisition, improvement and management of residential properties, with a goal of providing attainable workforce housing to 250,000 residents. It is a growth-oriented fund largely operating in the secondary and tertiary markets of the Sunbelt, with an annual target of 11-13%. DLP Preferred Credit Fund: The DLP Preferred Credit Fund focuses on mortgage loan origination and acquisition for non-owner-occupied single-family and multifamily assets. Loans generally range from six to 24 months, which increases liquidity and largely insulates fund investors from rising interest rates. The fund’s strategy involves rigorous vetting of borrowers and prioritizing seasoned real estate sponsors, with targeted returns of 10-11% The DLP Housing Fund: The DLP Housing Fund invests in multifamily rental communities, with a goal of 100,000 affordable workforce housing units. The fund offers tax advantages, flexible redemption options and 10-12% targeted annual returns, making it an attractive option for investors seeking both financial gains and social impact. Investing Wisely With DLP Capital For those interested in passive real estate investing, DLP Capital may present a unique approach to investing in the real estate market. Its thoughtful blend of growth and social responsibility provides investors with passive returns while empowering affordable workforce housing. DLP Capital’s offerings could play a significant role in an investor's passive income strategy, but as with all investments, it's still essential to align these opportunities with individual financial goals and risk tolerance. Nevertheless, real estate is a tried and true vehicle for passive wealth generation, and DLP Capital's funds deliver potentially appealing options to capitalize on that growth. Secure your financial future by tapping into the power of passive income with DLP Capital. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 06, 2024 08:15 AM Eastern Standard Time

CytoReason’s AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development

OurCrowd

By Meg Flippin, Benzinga Click here to learn more about CytoReason and how to invest through OurCrowd. Big data is transforming everything from the way we drive to the way we shop or even the way we consume energy. But when it comes to healthcare and fighting diseases, it still takes 10 or more years to bring a drug or treatment to market. What’s more, 90% of drugs in development fail. A big reason is that all the disparate data being collected from doctors, hospitals, clinical trials and patient outcomes reside in silos – thus not functioning together, and that only seems poised to get worse. The volume of human molecular data is growing rapidly, but analytic capabilities aren’t keeping up. That is essentially slowing progress in finding potential cures and more effective treatments. To overcome this challenge, a platform that can digest, organize and make sense of all the different data types and sources is needed – and that’s where CytoReason and its Disease Model Platform come in. Founded in 2016 to address this problem, CytoReason created what the company says is the first AI model to map treatments, patient groups and disease mechanisms while constantly evolving and learning. Bringing It All Together Researchers of all levels can rely on CytoReason’s proprietary data and innovative technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios. Never before has there been that much data organized and analyzed on one platform, says CytoReason. Similar to how navigation apps provide layers of data about streets, buildings and addresses, CytoReason's Disease Model Platform offers layers of pre-computed data, which can include results from clinical trials, data on proteins and single-cell data. With multiple models for various diseases, users of the platform can identify potential targets, prioritize treatments, stratify patients and find possible drug combinations. User-generated data can also be integrated, and hypotheses across different treatments can be tested. The platform learns with you and can help you understand the cause of the disease and identify potential R&D avenues for prevention. Giving Pharma An Edge For drug development companies and researchers, CytoReason says the biggest advantage of its Disease Model Platform is its ability to compare assets across different diseases. With a single standard for all disease models, users can answer critical questions including which patients may benefit most from the drug, what other diseases the drug can be developed for, and how the drug stacks up against the drugs currently available. By answering those questions, decision-makers in pharma and biotech companies can find new opportunities, increase success rates and shorten the drug development cycle. Sounds too good to be true? The platform is already being used by five of the top ten pharma companies including Sanofi SA (NASDAQ: SNY), Pfizer Inc. (NYSE: PFE). Sanofi, which tapped CytoReason’s AI platform for use in the field of inflammatory bowel disease (IBD) expanded its multiyear collaboration last year. Sanofi is using the platform to identify patient subtypes and pair them with IBD targets. Under the terms of the expanded agreement, Sanofi will pay CytoReason an undisclosed multimillion-dollar amount. Pfizer, which has been working with CytoReason since 2019, also extended its collaboration, announcing in 2022 that it committed a $20 million equity investment, has options to license CytoReason’s platform and disease models and fund supplementary project support in a deal potentially worth up to $110 million over the next five years. Since the two began collaborating, Pfizer has used CytoReason's biological models in its research to enhance the understanding of the immune system as it develops innovative drugs for immune-mediated and immuno-oncology diseases. CytoReason's platform has provided Pfizer with multiple insights in its research and development programs across over 20 diseases. CytoReason’s platform has also benefited Poolbeg Pharma, which has been using it to find novel approaches for treating influenza. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s disease model platform led to the discovery of multiple novel drug targets for the treatment of influenza. Big data is growing exponentially, particularly in the healthcare field, but getting it under one roof has proven difficult. It's the reason it takes so long to develop drugs and why the majority of them fail. Platforms like CytoReason are working to change that, providing AI-generated insights to understand disease mechanisms and disease progression, as well as potential treatment methods. In a world where data is endless, CytoReason is making sense of it all. To learn more about CytoReason and its novel approach to data click here. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Lisa Graston lisa.graston@ourcrowd.com Company Website http://www.ourcrowd.com

February 06, 2024 08:10 AM Eastern Standard Time

LIVE WORLD-WIDE TELETHON TO HELP FIGHT HOMELESSNESS AND BENEFIT THE LAS VEGAS RECUE MISSION DEBUTS LEADING UP TO THE BIG GAME

YourUpdateTV

Las Vegas Rescue Mission announced today that they will play host to the 1st Annual Alvin James, Approaching Life Under the Bridge Telethon on Wednesday, February 7th, 2024, from The Chapel, at their Las Vegas Rescue Mission location. This groundbreaking special event will be hosted by actor, musician, and former NFL player Julian Horton, and is sponsored by Door2Door Anywhere.com. All proceeds from the on-line telethon will go directly to the Las Vegas Rescue Mission as they have been recognized for the impactful work they are doing in the Las Vegas area. A video accompanying this announcement is available at: https://vimeo.com/910236902/36f170d396?share=copy The Alvin James, Approaching Life Under the Bridge Telethon is the brainchild of musician / songwriter and Executive Producer McKinley Horton who wanted to take his passion for fighting homelessness in the US to the next level and at the same time, honor one of his mentors, the late Alvin James. “Alvin James inspired me to look deeply into myself and my desire to help those in need it in any way I could, and with his recent passing last fall, I decided that the time was right “says Horton. The concept Mr. Horton came up with was to create a meaningful live event that not only includes an array of entertainers, but to also focus on the great work local non-profits are doing and try to shed light on their great work, the staff and volunteers that they have, and help them raise funds to benefit their programs and increase the impact they have on those who rely on them and the services they provide. “We all know how hard it is for local non-profits that deal with the homeless and other members of the underserved communities nation-wide face when it comes to financial support, so we decided to make sure 100 percent of all proceeds go directly to the local non-profit so that they can do what they do best which is help the people who need it.” Horton added. The result of that thinking was to honor the non-profit that is selected by The Alvin James, Approaching Life Under the Bridge selection committee, to coincide with a time of year where everyone is focused on an annual event and there is no event bigger than the annual big game. “As a sports fan and the father of a former NFL player, the committee and I came up with the idea of doing our telethon during the week before the big game in the city that the big game takes place” said Horton whose son, actor, musician and former NFLer, Julian Horton, will be one of the telethons host “so its so great to be partnering with the Las Vegas Rescue Mission, who the committee felt deserved the spotlight, for the amazing work we got to see first hand when we visited them “ Las Vegas Rescue Mission CEO, Heather Engle is super supportive of the goals of the Alvin James, Approaching Life Under the Bridge Telethon and with the Las Vegas Rescue Mission (LVRM ) as its partner, in what will now be an annual event with the 2nd Annual Telethon taking place in New Orleans site of the next Big Game, Engle and the staff at LVRM have also played a big role in getting the event off the ground. “Anytime we can get to share our mission statement with a wide audience we are always thankful and willing to help. This event will not only help people here in Las Vegas, but we hope to shed a brighter light on what we all know is as a major problem world-wide.We serve over 1,000 meals a day and have programs that not only deal with homelessness, but other important issues like addiction and mental health so we are very happy to be a part of this amazing event “ Engle noted Door2Door Anywhere.com, one of the world’s leading transportation companies, led by CEO Rattan Joea, is the sole sponsor of this years event and as Joea explains, the brand couldn’t be happier to be involved with the Alvin James, Approaching Life Under the Bridge Telethon for more than just brand exposure “For me and Door2Door Anywhere.com this isn’t about brand exposure, it’s about helping people, which has always been a part of my personal brand as well as our DOOR2Door Anywhere identity. We transport people all over the world and have a real worldview of the issues humanity is facing so to be able to play a role in helping the homeless and other underserved members of communities everywhere is vital to me..Our sponsorship of this 1st annual event is just the beginning of what we think will be a huge event going forward that will help people so we are all in and will be with the Telethon in Vegas this year, and then on to New Orleans next year, “ said Joea Host Julian Horton, (whose acting credits include a featured role in the hit film, National Champions, along with TV credits on Tyler Perry’s “Bruh”, Tough Love Atlanta, and others) didn’t need to be recruited by his father, his desire and passion to help change the lives of those less fortunate started at an early age. “ My passion has always been about helping those less fortunate than me …I was lucky, I’ve he had support throughout my life and I know how important it is to have that and when I see all the hurt, harm and pain going down on the streets these days as well as the struggle those without homes, support, and love face every minute of their lives…I just cant sit back and act like it isn’t there so I’m asking EVERYONE out there to tune in” For more information about the live stream and to donate go to www.vegasrescue.org and click on the events tab for THE ALVIN JAMES, APPROACHING LIFE UNDER THE BRIDGE TELETHON About the Las Vegas Rescue Mission: The Las Vegas Rescue Mission (LVRM) was founded in 1970 by a pastor and six businessmen who had calling to help those who were homeless and hungry. Together, they secured a tiny storefront at 414 West Bonanza Road. By God’s grace, they provided sandwiches and drinks, along with mats and blankets for men to eat and sleep away from the elements. LVRM is more than just a shelter, we stand as a beacon of hope. We continue to adapt to meet the needs of men, women, and their children in an ever-changing society. Through effective, innovative Christian recovery programs, the Mission provides a path for those who want to escape the despair of the streets. For more information about the live stream and to donate go to www.vegasrescue.org and click on the events tab for THE ALVIN JAMES, APPROACHING LIFE UNDER THE BRIDGE TELETHON Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 06, 2024 08:00 AM Eastern Standard Time

Video

1 ... 441 442 443 444 445 ... 3763